Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KKATK
ADC Name
SHR-A2102
Synonyms
SHR A2102; SHR-A2102; SHRA2102
   Click to Show/Hide
Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.
Drug Status
Phase 3
Indication
In total 3 Indication(s)
Urothelial cancer
Phase 3
Clinical Trial
Pancreatic cancer
Phase 2
Clinical Trial
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Nectin-4 (NECTIN4)
  Antigen Info 
Payload Name
9106-IM-2
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
SHR169106
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05735275
Phase 1
Safety, tolerability, pharmacokinetics, and efficacy of SHR-A2102, in subjects with locally advanced or metastatic solid tumor malignancies: a phase 1 open-label, one-arm, multicenter study.
Undisclosed  NCT05701709
Phase 1
An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SHR-A2102 in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05735275  Clinical Status Phase 1
Clinical Description Safety, tolerability, pharmacokinetics, and efficacy of SHR-A2102, in subjects with locally advanced or metastatic solid tumor malignancies: a phase 1 open-label, one-arm, multicenter study.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05701709  Clinical Status Phase 1
Clinical Description An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SHR-A2102 in patients with advanced solid tumors.
References
Ref 1 Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A2102, In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies: A Phase I Open-Label, One-Arm, Multicenter Study.
Ref 2 An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors